Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839

  • Authors:
    • Hitoshi Zembutsu
    • Yasuyuki Ohnishi
    • Yataro Daigo
    • Toyomasa Katagiri
    • Takefumi Kikuchi
    • Soji Kakiuchi
    • Chiyoko Nishime
    • Koichi Hirata
    • Yusuke Nakamura
  • View Affiliations

  • Published online on: July 1, 2003     https://doi.org/10.3892/ijo.23.1.29
  • Pages: 29-39
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To date, no single or multiple molecular markers have been successful in predicting sensitivity of individual patients to anti-cancer drugs. As the nature of a specific cancer is considered to be defined by the proteins being expressed in the tumor cells, systematic analysis of gene-expression profiles may provide information reflecting sensitivity of a given tumor to certain drugs. Recent progress in genome technology has enabled us to examine expression profiles of thousands of genes in a single experiment. We used this approach to examine 13 xenografts of human tumors implanted into nude mice for sensitivity to an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (Iressa). To identify genes that might be associated with sensitivity to this drug we used a cDNA microarray representing 23,040 genes to analyze expression profiles of the 13 xenografts and identified 114 genes whose expression levels correlated significantly with sensitivity of the tumors to ZD1839. We then investigated alteration of expression profiles in response to the ZD1839 treatment in four non-small cell lung cancer (NSCLC) xenografts, of which two (LC6 and LC11) were sensitive and the other two (Lu116 and L27) were resistant to this EGFR-TKI. Systematic analysis of expression at various time points during oral treatment for 14 days, compared with corresponding untreated samples, identified a set of genes whose expression levels changed in the two sensitive tumors but not in the two resistant tumors. The data obtained here should provide useful information on the molecular mechanism underlying clinical responses to EGFR-TKIs, aid the development of novel therapies for lung cancer, and potentially identify predictive molecular markers for sensitivity to ZD1839.

Related Articles

Journal Cover

July 2003
Volume 23 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zembutsu, H., Ohnishi, Y., Daigo, Y., Katagiri, T., Kikuchi, T., Kakiuchi, S. ... Nakamura, Y. (2003). Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839. International Journal of Oncology, 23, 29-39. https://doi.org/10.3892/ijo.23.1.29
MLA
Zembutsu, H., Ohnishi, Y., Daigo, Y., Katagiri, T., Kikuchi, T., Kakiuchi, S., Nishime, C., Hirata, K., Nakamura, Y."Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839". International Journal of Oncology 23.1 (2003): 29-39.
Chicago
Zembutsu, H., Ohnishi, Y., Daigo, Y., Katagiri, T., Kikuchi, T., Kakiuchi, S., Nishime, C., Hirata, K., Nakamura, Y."Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839". International Journal of Oncology 23, no. 1 (2003): 29-39. https://doi.org/10.3892/ijo.23.1.29